Skip to main content
. 2012 May 4;119(25):6145–6154. doi: 10.1182/blood-2011-12-395970

Figure 5.

Figure 5

Overall survival after rituximab prophylaxis exceeds 70%. For the CLL patients, the 4-year overall survival was 73% (95% CI, 57%-94%) and freedom from progression was 47% (95% CI, 30%-75%). For the MCL patients, the 4-year overall survival was 69% (95% CI, 48%-99%) and freedom from progression was 53% (95% CI, 31%-89%).